$96.3 Million is the total value of Knoll Capital Management, LLC's 37 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 51.9% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ALDX | Buy | Aldeyra Therapeutics Inc | $20,253,192 | -20.0% | 3,031,915 | +0.5% | 21.02% | -31.5% |
APLT | Buy | Applied Therapeutics Inc | $12,853,599 | +191.1% | 5,162,088 | +49.6% | 13.34% | +149.2% |
BHVN | Buy | Biohaven Pharmactl Hldg Co L | $12,755,876 | +18.4% | 490,422 | +8.9% | 13.24% | +1.4% |
AVDL | Buy | Avadel Pharmaceuticals Plcsponsored adr | $6,180,000 | -25.0% | 600,000 | +20.0% | 6.42% | -35.8% |
HOOK | HOOKIPA PHARMA | $3,398,709 | -30.0% | 5,517,385 | 0.0% | 3.53% | -40.1% | |
VRNA | Verona Pharmasponsored ads | $3,260,000 | -22.9% | 200,000 | 0.0% | 3.38% | -34.0% | |
SA | Buy | SEABRIDGE GOLD INC | $2,601,598 | +169.9% | 246,597 | +208.2% | 2.70% | +131.1% |
GDX | Vaneck Gold Miners ETFgold miners etf | $2,471,683 | -10.6% | 91,850 | 0.0% | 2.57% | -23.5% | |
SIL | Global X Silver Miners ETF 37954Y848global x silver | $2,143,830 | -8.0% | 89,700 | 0.0% | 2.22% | -21.3% | |
KGC | New | Kinross Gold Corp | $2,006,400 | – | 440,000 | +100.0% | 2.08% | – |
FNV | Buy | Franco Nev Corp CAD | $1,935,605 | +93.9% | 14,500 | +107.1% | 2.01% | +66.0% |
WPM | New | Wheaton Precious Metals Corp | $1,926,125 | – | 47,500 | +100.0% | 2.00% | – |
AEM | New | Agnico Eagle Mines Ltd | $1,818,000 | – | 40,000 | +100.0% | 1.89% | – |
SILV | Buy | Silvercrest Metals Inc CAD | $1,808,100 | +81.5% | 410,000 | +141.2% | 1.88% | +55.4% |
ENTX | Entera Bio Ltd | $1,801,099 | -14.0% | 2,484,275 | 0.0% | 1.87% | -26.3% | |
EQX | New | Equinox Gold Corp | $1,780,529 | – | 420,929 | +100.0% | 1.85% | – |
GDXJ | Vaneck Junior Gold Miners ETFjunior hold mine | $1,713,024 | -9.6% | 53,150 | 0.0% | 1.78% | -22.6% | |
MAG | New | Mag Silver Corp | $1,659,200 | – | 160,000 | +100.0% | 1.72% | – |
BAH | Booz Allen Hamilton HLDG CORcl a | $1,420,510 | -2.1% | 13,000 | 0.0% | 1.48% | -16.1% | |
AG | New | First Majestic Silver Corp | $1,410,750 | – | 275,000 | +100.0% | 1.46% | – |
V | Visa | $1,115,548 | -3.1% | 4,850 | 0.0% | 1.16% | -17.0% | |
TMO | Thermo Fischer Scientific Inc | $1,062,957 | -3.0% | 2,100 | 0.0% | 1.10% | -16.9% | |
CVS | CVS Health Corp | $1,012,390 | +1.0% | 14,500 | 0.0% | 1.05% | -13.5% | |
MO | Altria Group Inc | $954,535 | -7.2% | 22,700 | 0.0% | 0.99% | -20.5% | |
NOC | Northrop Grumman Corp | $953,011 | -3.4% | 2,165 | 0.0% | 0.99% | -17.3% | |
AGI | New | Alamos Gold Inc | $903,200 | – | 80,000 | +100.0% | 0.94% | – |
LMT | New | Lockheed Martin Corp | $879,264 | – | 2,150 | +100.0% | 0.91% | – |
RGLD | New | Royal Gold Inc. | $802,791 | – | 7,550 | +100.0% | 0.83% | – |
PAAS | New | Pan American Silver Corp | $783,150 | – | 54,085 | +100.0% | 0.81% | – |
OR | OSISKO GOLD ROYALTIES LTD | $732,000 | -24.5% | 400,000 | 0.0% | 0.76% | -35.3% | |
New | Amylyx | $453,575 | – | 24,772 | +100.0% | 0.47% | – | |
ORGS | Orgenesis, Inc. | $393,537 | -55.4% | 634,738 | 0.0% | 0.41% | -61.8% | |
Omega Therapeutics Inc. | $371,971 | -61.6% | 173,010 | 0.0% | 0.39% | -67.1% | ||
OCUP | Ocuphire Pharma Inc. | $335,000 | -22.8% | 100,000 | 0.0% | 0.35% | -33.8% | |
NEWP | New | New Pac Metals Corp | $233,027 | – | 131,654 | +100.0% | 0.24% | – |
BTAI | Buy | BioXcell | $151,800 | -24.0% | 60,000 | +100.0% | 0.16% | -34.7% |
OCUL | Sell | Ocular Therapeutix Inc. | $1,256 | -99.9% | 400 | -99.8% | 0.00% | -99.9% |
ALT | Exit | Altimmune Inc | $0 | – | -173,864 | -100.0% | -0.74% | – |
OCUL | Exit | Ocular Therapeutix Inc.call | $0 | – | -95,800 | -100.0% | -0.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
Soligenix Inc. | 20 | Q3 2022 | 1.7% |
Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-01-16 |
13F-HR | 2023-11-14 |
SC 13G | 2023-10-04 |
13F-HR | 2023-08-15 |
SC 13G | 2023-06-20 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
SC 13G | 2023-01-23 |
13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.